Angion Biomedica Corp expected to post a loss of 62  cents a share - Earnings Preview

Elicio Therapeutics

25/03/2022 11:30

* Angion Biomedica Corp  ANGN.OQ   ANGN.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 28
(estimated). 
    * The Uniondale New York-based  company is expected to
report  a
278.5% increase in revenue to $1.738 million from $459 thousand
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Angion Biomedica
Corp is
for a loss of 62 cents per share. For the same quarter last
year, the company reported a loss of $1.90 per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Angion
Biomedica
Corp is $8​, above​ its last closing price of $2.29. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.72       -0.72      -0.53     Beat    26.9
 Jun. 30 2021  -0.69       -0.69      -0.58     Beat    15.6
 Mar. 31 2021  -0.62       -0.62      -1.56     Missed  -150.6
                                                        ​
 Dec. 31 2020  -1.30       -1.30      -1.90     Missed  -46.2
 ​​                                                     
                                                        ​
 This summary was machine generated March 25 at 11:30 GMT.  All
figures in US dollars  unless otherwise stated